Healthcare expenditure and its socio-demographic and clinical predictors in Australians with poorly controlled asthma

Introduction Asthma has substantial and increasing health and economic burden worldwide. This study aimed to estimate healthcare expenditure and determine the factors that increase expenditure in Australians with poorly controlled asthma. Methods Individuals ≥18 years of age with poorly controlled asthma, as determined by a score ≥1.5 on the Asthma Control Questionnaire, were included in the study. Healthcare utilization costs from medical services and medications were estimated over an average follow-up of 12 months from administratively linked data: the Medicare Benefits Schedule and Pharmaceutical Benefits Scheme. A generalized linear model with gamma distribution and log link was used to predict participants’ key baseline characteristics associated with variations in healthcare costs. Results A total of 341 participants recruited through community pharmacies were included. The mean (standard deviation, SD) age of participants was 56.6 (SD 17.6) years, and approximately 71% were females. The adjusted average monthly healthcare expenditure per participant was $AU386 (95% CI: 336, 436). On top of the average monthly costs, an incremental expenditure was found for each year increase in age ($AU4; 95% CI: 0.78, 7), being unemployed ($AU201; 95% CI: 91, 311), one unit change in worsening quality of life ($AU35; 95% CI: 9, 61) and being diagnosed with depression and anxiety ($AU171; 95% CI: 36, 306). Conclusions In a cohort of Australian patients, characterized by poor asthma control and co-morbidities individuals impose substantial economic burden in terms of Medicare funded medical services and medications. Programs addressing strategies to improve the quality of life and manage co-morbid anxiety and depression and encourage asthma patients’ engagement in clinically tolerable jobs, may result in significant cost savings to the health system.

[1]  Christoph Flückiger Alliance , 2022, Cognitive and Behavioral Practice.

[2]  S. Bosnic-Anticevich,et al.  A Targeted Approach to Improve Asthma Control Using Community Pharmacists , 2021, Frontiers in Pharmacology.

[3]  D. Sinclair,et al.  The economic value of targeting aging , 2021, Nature Aging.

[4]  T. Mahr,et al.  The Projected Economic and Health Burden of Uncontrolled Asthma in the United States , 2020, Pediatrics.

[5]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[6]  J. Upham Asthma in Children and Adults – What are The Differences and What Can They Tell us About Asthma? , 2020, Frontiers Research Topics.

[7]  E. Denton,et al.  Asthma in Children and Adults—What Are the Differences and What Can They Tell us About Asthma? , 2019, Front. Pediatr..

[8]  H. Inoue,et al.  A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan , 2019, npj Primary Care Respiratory Medicine.

[9]  M. Yaghoubi,et al.  The Projected Economic and Health Burden of Uncontrolled Asthma in the United States , 2019, bioRxiv.

[10]  N. Alvis-Guzmán,et al.  Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis , 2018, The World Allergy Organization journal.

[11]  C. Janson,et al.  Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR) , 2018, Respiratory Research.

[12]  S. Hiles,et al.  Health‐related quality of life burden in severe asthma , 2018, The Medical journal of Australia.

[13]  M. Sadatsafavi,et al.  The projected economic and health burden of sub-optimal asthma control in Canada. , 2018, Respiratory medicine.

[14]  M. Sambasivan,et al.  A review of the Australian healthcare system: A policy perspective , 2018, SAGE open medicine.

[15]  T. H. Nguyen,et al.  Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet. Respiratory medicine.

[16]  K. Sanderson,et al.  Costs associated with hereditary haemochromatosis in Australia: a cost-of-illness study. , 2017, Australian health review : a publication of the Australian Hospital Association.

[17]  L. Murphy,et al.  State-level medical and absenteeism cost of asthma in the United States , 2017, The Journal of asthma : official journal of the Association for the Care of Asthma.

[18]  H. V. Nguyen,et al.  Association between asthma control and asthma cost: Results from a longitudinal study in a primary care setting , 2017, Respirology.

[19]  D. Newcomb,et al.  Mechanisms Driving Gender Differences in Asthma , 2017, Current Allergy and Asthma Reports.

[20]  I. Pavord,et al.  The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β2-agonists in the United Kingdom: a cross-sectional analysis , 2017, npj Primary Care Respiratory Medicine.

[21]  M. Morais‐Almeida,et al.  Asthma costs and social impact , 2017, Asthma Research and Practice.

[22]  D. Price,et al.  Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study , 2016, Respiratory Research.

[23]  M. Merino,et al.  Cost Effectiveness of Outpatient Asthma Clinics , 2016 .

[24]  H. Brenner,et al.  Health service use and costs associated with excess weight in older adults in Germany. , 2015, Age and ageing.

[25]  Dan J Stein,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[26]  Marco Peters,et al.  Asthma control in Australia: a cross‐sectional web‐based survey in a nationally representative population , 2015, The Medical journal of Australia.

[27]  P. Kardos,et al.  Healthcare costs and resource utilization of asthma in Germany: a claims data analysis , 2015, The European Journal of Health Economics.

[28]  D. Globe,et al.  The relationship between asthma, asthma control and economic outcomes in the United States , 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

[29]  O. Kurt,et al.  Does gender affect asthma control in adult asthmatics? , 2014, Chronic respiratory disease.

[30]  M. Abramson,et al.  Asthma mortality in Australia in the 21st century: a case series analysis , 2013, BMJ Open.

[31]  E. Meltzer,et al.  Reliability, validity, and responsiveness of the Rhinitis Control Assessment Test in patients with rhinitis. , 2013, The Journal of allergy and clinical immunology.

[32]  Katrina A Cubit,et al.  Aging in Australia. , 2011, The gerontologist.

[33]  Anthony O'Hagan,et al.  Review of Statistical Methods for Analysing Healthcare Resources and Costs , 2010, Health economics.

[34]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[35]  C. Bucca,et al.  Asthma severity and medical resource utilisation , 2004, European Respiratory Journal.

[36]  Gerard J Fitzsimmons,et al.  From the Australian Institute of Health and Welfare , 2014, Communicable diseases intelligence quarterly report.

[37]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[38]  R. Andersen Revisiting the behavioral model and access to medical care: does it matter? , 1995, Journal of health and social behavior.

[39]  A. Woolcock,et al.  A scale for the measurement of quality of life in adults with asthma. , 1992, Journal of clinical epidemiology.